Loading stockRelated stocks: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and meaningful partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most.
$85.73
$2.11 (-2.40%)
EOD Jul 17, 2026
20.84% operating margin is above average. ROIC at 9.63%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue grew 11.5%, still solid. Margins contracted 4.5pp, which offsets some of the top-line progress.
At 46x earnings, the current multiple leaves limited room for execution misses or growth deceleration. ROIC dropped from 13.60% to 9.63%, capital efficiency is deteriorating.
45.6x earnings, 45.7x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$6.30B
▲ +11.5% YoY
Net Income (TTM)
$1.10B
▼ -74.3% YoY
Op. Margin
21.37%
▼ -4.5pp YoY
ROIC
10.15%
▼ -4.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1.09B
▲ +360.5% YoY
Op. Cash Flow (TTM)
$1.36B
▲ +194.2% YoY
Net Debt
-$2.97B
Net Cash Position
Cash & Equiv.
$3.67B
5Y CAGR: +6.7%
5Y CAGR: +15.6%
Continue Research
At a P/E of 45.6 and a price-to-free-cash-flow of 45.7, Edwards Lifesciences (EW) trades above a two-stage DCF intrinsic value of about $37.63 per share, so at $85.73 the stock looks overvalued (56.1% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Edwards Lifesciences scores 54/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $37.63 per share for EW, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $28.22. At today's $85.73, that puts the stock about 56.1% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Edwards Lifesciences scores 54 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 21.4% operating margin and a 10.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. EW currently trades above its estimated intrinsic value and scores 54/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.